

To: [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED]
Sent: Wed 9/23/2020 1:59:18 PM
Subject: FW: Transmittal of MSD COVID-19 vaccine candidates introductory presentation [Confidential]
Received: Wed 9/23/2020 1:59:18 PM
[COVID19 Programs For EC vFinal.pptx](#)
[SCRecomm MSD final EN.pdf](#)

Ho [REDACTED]
 Hierbij presentatie van Merck over hun 2 COVID vaccins in ontwikkeling en het advies van de fransen.
 Groeten,
 [REDACTED]

From: [REDACTED] <[REDACTED]@minvws.nl>
Sent: woensdag 23 september 2020 14:13
To: [REDACTED] <[REDACTED]@rivm.nl>; [REDACTED] <[REDACTED]@rivm.nl>
Subject: FW: Transmittal of MSD COVID-19 vaccine candidates introductory presentation [Confidential]

Ter info, zoals besproken, het eerste levensteken van MSD Merck. Er staat informatie in de presentatie over de twee kandidaten.

Groet,
 [REDACTED]

Van: [REDACTED] [REDACTED]@merck.com>
Verzonden: woensdag 23 september 2020 06:54
Aan: [REDACTED]@ec.europa.eu; [REDACTED] <[REDACTED]@minvws.nl>; [REDACTED]@aemps.es
Onderwerp: Transmittal of MSD COVID-19 vaccine candidates introductory presentation [Confidential]

Confidential

Dear [REDACTED], and [REDACTED]

On behalf of MSD, please accept our thanks for your guidance and advice over the last few weeks as we began our engagement with the European Commission on our COVID-19 vaccine programs. MSD is working tirelessly to bring forward solutions to help end this pandemic and we are pleased to share information on our vaccine programs with the Commission and Member States. Our portfolio approach of two live replicating viral vector vaccine candidates (V590 and V591) has the potential for high efficacy and durability and a differentiated dosing and administration profile. As such, we believe that these candidates will help to further diversify the European portfolio of COVID-19 vaccine candidates.

I have attached to this email a slide deck that provides an overview of MSD's vaccines business and legacy, our V590 and V591 programs, and our manufacturing scale-up plan. Importantly, we are already working to scale-up manufacturing in Europe to provide flexible capacity across V590 and V591, with the goal of supplying vaccine doses to Europe and to LMICs/LICs from this manufacturing node. Safety and quality are of paramount importance in our development programs and in our manufacturing expansion activities and our goal is to provide global, equitable access to safe, efficacious COVID-19 vaccines.

We very much appreciate the Steering Board's consideration of our programs and request that the attached information be limited to these discussions. We look forward to hearing from you regarding next steps and are available at the Board's convenience to clarify points and respond to questions.

Thank you again for your guidance and assistance.

Kindest regards,
 [REDACTED]

[REDACTED]
 [REDACTED]

Global Vaccines Public Policy, Partnerships,
 & Government Affairs

Merck & Co.

5.1.2e @merck.com

+1 5.1.2e

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.